Latest Headlines

Latest Headlines

EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand

EpiVax and Novozymes have joined forces, attaching an autoimmune drug to a delivery protein--and by doing so the companies hope to carve themselves a $3 billion piece out of the global autoimmune market.

Repligen shares tank on expected FDA rejection

Repligen put out the word this morning that the FDA has cancelled an expert panel review of its pancreatic imaging agent.

Repligen snags Novozymes business in $28.3M deal

Repligen has made a move to boost its biomanufacturing capacity and its commercial prospects. The Waltham, MA-based biotech says it grabbed Novozymes Biopharma Sweden for $22.7 million (€17